Introduction
Peroxisome proliferators are a diverse class of chemicals that induce a pleiotropic response and hepatocarcinogenesis when administered to rodents (1-3). Short-term administration of peroxisome proliferators results in hepatomegaly and altered expression of genes encoding peroxisomal, mitochondrial and microsomal lipid metabolizing enzymes (reviewed in refs 4, 5) . Among the best characterized of these proteins is the peroxisomal β-oxidizing enzyme acyl CoA oxidase (ACO), the rate limiting enzyme responsible for initiating peroxisomal fatty acyl CoA oxidation (6, 7) . In contrast, expression of genes encoding apolipoprotein A-I, C-III and others are reduced after exposure to peroxisome proliferators (8) (9) (10) .
Peroxisome proliferator-induced changes in gene expression are mediated by the peroxisome proliferator-activated receptor α (PPARα), a member of the nuclear receptor superfamily.
Abbreviations: ACO, acyl CoA oxidase; PCNA, proliferating cell nuclear antigen; PPARα, peroxisome proliferator-activated receptor α; PPRE, proliferator responsive elements.
On activation by peroxisome proliferators, PPARα forms a heterodimer with retinoid-X-receptor and the resulting complex then binds to peroxisome proliferator responsive elements (PPRE) located in promoter regions of target genes that are regulated by PPARα. There is a growing list of genes that contain PPREs whose expression is altered by PPARα (reviewed in ref. 11 ).
Long-term administration of peroxisome proliferators causes hepatocarcinogenesis in rodents. The mechanisms underlying this effect are unclear but could be the result of alterations in gene expression mediated by PPARα. Most responses induced by peroxisome proliferators in rodent liver are dependent on PPARα. For example, hepatomegaly, increases in cell proliferation as measured by increases in replicative DNA synthesis, altered expression of genes encoding peroxisomal, mitochondrial and microsomal enzymes, and hepatocarcinogenesis are all responses induced by peroxisome proliferators that require PPARα (12) (13) (14) . While it is clear that PPARα mediates these effects, the precise mechanisms are unknown.
Two non-exclusive hypotheses have been postulated to account for peroxisome proliferator-induced carcinogenicity. Peroxisome proliferators cause large increases in hepatic ACO expression that is not accompanied by a similar increase in catalase. Thus increased intracellular H 2 O 2 resulting from ACO catalytic activity has been hypothesized to contribute to the carcinogenic effect of peroxisome proliferators (15) since H 2 O 2 is capable of causing DNA damage through the formation of adducts such as 8-hydroxydeoxyguanine or strand breaks. Sustained alterations in cell proliferation (16, 17) , apoptosis (18, 19) , or both, also occur as a result of peroxisome proliferator administration, and these changes have been postulated to contribute to the underlying mechanism of peroxisome proliferator-induced hepatocarcinogenicity (20) . In support of the latter hypothesis, Wy-14,643 was recently shown to cause a discordant expression of a number of cell cycle control proteins, including proliferating cell nuclear antigen (PCNA), cyclins and cyclin-dependent kinases (CDK) (21) (22) (23) . In this work, the effect of Wy-14,643 on cell cycle regulatory proteins and ACO expression patterns in wild-type and PPARα-null mice was compared to determine whether these effects are dependent on PPARα under conditions known to result in liver carcinogenesis in wild-type mice but not in PPARα-null mice.
Materials and methods

Dietary treatment and tissue collection
Tissue samples used in this study were obtained from mice treated as described below from a previously published experiment (14) . Seven-to eight-weekold, wild-type (ϩ/ϩ) or PPARα-null (-/-) male mice on an Sv/129 background (F 4 generation) were housed 4-5 animals per cage in a temperature-and lightcontrolled environment (T ϭ 25°C, 12 h light-dark cycle). Mice were fed a pelleted mouse chow containing either 0.0 (control) or 0.1% 4-chloro-6-(2,3-xylidino)-pyrimidynylthioacetic acid (Wy-14,643) provided ad libitum for either 5 weeks or 11 months. After treatment, the mice were euthanized and necropsied. Liver samples were obtained and snap-frozen until further analysis. Protein analysis Nuclear extracts were prepared from livers of mice fed for either 5 weeks or 11 months as previously described (24) . Hepatic nuclear extracts from (ϩ/ϩ) mice fed the Wy-14,643 diet for 11 months were prepared from tissue with no grossly visible tumors. From 10 to 50 µg of protein were separated by SDS-PAGE and electrophoretically transferred to a nitrocellulose membrane by electroblotting in standard Tris-glycine buffer. For analysis of pure ACO (25) , 0.5 µg of ACO was separated with SDS-PAGE and transferred as described above. Proteins were visualized with Coomassie Blue stain using standard techniques. To better differentiate the MW of immunoreactive proteins of~70 kDa, 10 µg of protein was loaded for western blot analysis of cyclin B1, PCNA, c-myc and ACO. Immunodetection was performed using specific primary antibodies followed by conjugation with a secondary, horseradish peroxidase-labeled antibody and then detected with a chemiluminescence kit (ECL; Amersham Life Science, Cleveland, OH). The primary antibodies used included those raised against mouse ACO, cyclin B1, cyclin D1, cyclin E, CDK-1 (cdc2 p34), CDK-2, CDK-4, PCNA, p53 and c-myc. Antibodies were purchased commercially (Santa Cruz Biotechnology, Santa Cruz, CA) except for the ACO antibody, which was developed and characterized in an earlier report (25) . Analysis of liver samples from four mice per group was performed, although representative immunoblots from two separate mice from each group are presented in the figures shown in the text. mRNA analysis RNA samples from liver with no grossly visible tumors were obtained and analyzed essentially as previously described (13) . Seven cDNA probes previously described were used for sequential northern blot analysis, including mouse CDK-1, CDK-2, CDK-4, cyclin B1, cyclin D1, c-myc and β-actin (13, (26) (27) (28) (29) (30) . A mouse PCNA cDNA was obtained by reverse transcription PCR from 0.5 µg of total RNA isolated from Wy-14,643-treated mouse liver. The PCR primers selected were based on the published cDNA sequence of mouse PCNA (31) . The second strand cDNA was amplified by subsequent PCR with the designed primers. The forward PCR primer for mouse PCNA was 5Ј-CTCACGTCTCCTTGGTACAGCTTAC-3Ј (271-295). The reverse PCR primer for mouse PCNA was 5Ј-CTTCCTCATCTTCAATCTTGGGAG-3Ј (921-898). The amplified cDNA fragment for mouse PCNA was 651 bp corresponding to nt 271-921 and its identity was confirmed by sequencing.
Results
Analysis of total hepatic nuclear proteins separated by SDS-PAGE revealed significant differences in expression patterns in (ϩ/ϩ) mice fed Wy-14,643 for either 5 weeks ( Figure 1A ) or 11 months ( Figure 1B ) compared with untreated controls. A protein with an apparent mol. wt of~70 kDa was very abundant in liver samples from (ϩ/ϩ) mice fed Wy-14,643 compared with control samples, and the increase in staining intensity was highest among all other proteins visualized on the gel (Figure 1 ). Nuclear proteins from (ϩ/ϩ) mice fed Wy-14,643 also had higher levels of at least four other proteins with apparent mol. wts of~65,~50,~43 and~35 kDa compared with untreated control samples (Figure 1 ). In addition, several proteins with apparent mol. wts of~150,~130 and~94 kDa were present at lower concentrations in (ϩ/ϩ) mice fed Wy-14,643 as compared with controls. Protein expression patterns in samples from (ϩ/ϩ) mice fed Wy-14,643 for either 5 weeks or 11 months were virtually identical, as visualized by Coomassie staining and none of these changes in protein expression patterns was observed in the (-/-) mice fed Wy-14,643 for either time frame (Figure 1) .
Analysis of specific proteins by western blots also revealed differential effects of Wy-14,643 in the (ϩ/ϩ) and (-/-) mice. Hepatic ACO was markedly induced in (ϩ/ϩ) mice fed Wy-14,643 for either 5 weeks or 11 months compared with untreated controls (Figure 2 ). The immunoreactive proteins detected with an anti-ACO antibody with apparent mol. wts of~70 and~50 kDa were consistent with previous reports (25, 32) . These data suggest that the large increase in the~70 kDa protein observed with Coomassie staining represents ACO, which is known to be induced by~20-fold in response to peroxisome proliferators (6, 33) . This increase in ACO was not observed in samples from (-/-) fed Wy-14,643 ( Figure 2 ). Levels of ACO in both groups of (-/-) mice were similar to levels from control (ϩ/ϩ) mice.
Proteins involved with cell proliferation and cell cycle regulation were also altered as a result of Wy-14,643 administration in (ϩ/ϩ) mice as assessed by western blot analysis. Increases in CDK-1, CDK-2, CDK-4, PCNA and c-myc, with apparent mol. wts of~34,~36,~34,~37 and~65 kDa, respectively, were detected in hepatic nuclear proteins from (ϩ/ϩ) mice fed Wy-14,643 compared with controls ( Figure  3 ). This effect was not present in hepatic nuclear samples from (-/-) mice fed Wy-14,643. Differences in expression patterns of cyclin B1, cyclin D, cyclin E or p53 were not found in samples from (ϩ/ϩ) mice fed Wy-14,643 for either 5 weeks or 11 months (Figure 3) . For cyclin B1, no significant expression of this~62-kDa protein was detected at the level of sensitivity of our assay. However, highly immunoreactive proteins with apparent mol. wts of~70,~50 kDa, or both, were found in samples from (ϩ/ϩ) mice fed Wy-14,643 with a number of the antibodies used in this work, including cyclin B1, CDK-1, PCNA and c-myc (as illustrated for cyclin B1 and c-myc in Figure 3 ). This effect was not observed in samples from (-/-) mice fed Wy-14,643.
Immunoblot analysis of pure ACO was performed to test the hypothesis that the immunoreactive protein we detected with antibodies against cyclin B1, CDK-1, PCNA and c-myc was actually ACO. Indeed, antibodies raised against PCNA, CDK-1, cyclin B1 and c-myc were all immunoreactive with both the~70 kDa and~50 kDa subunits of ACO (Figures 2  and 4 ). Coomassie staining of ACO showed that this sample contained much less of the~70 kDa subunit than the~50 kDa protein. Further, the staining intensity correlated well with the immunoreactivity for the respective subunits of ACO ( Figure 4 ). Northern blot analysis was consistent with the increase in CDK-1, CDK-4 and c-myc expression observed as a result of Wy-14,643 feeding. Increased levels of CDK-1, CDK-4 and c-myc mRNA were found after 5 weeks of feeding Wy-14,643 to wild-type mice, and this effect was not observed in PPARα-null mice fed with similar diets ( Figure 5 ). In contrast to results obtained with western analysis, which revealed no change in protein, northern analysis revealed a significant increase in cyclin D1 mRNA in (ϩ/ϩ) mice fed Wy-14,643 compared with controls ( Figure 5 ). This effect was not observed in (-/-) mice treated with Wy-14,643. The mRNA encoding CDK-2 was not detected in any of the groups (data not shown) the mRNA encoding PCNA was detected at similar levels in all groups ( Figure 5 ). Lastly, mRNA encoding cyclin B1 was not different between untreated and treated (ϩ/ϩ) mice; however, levels of this mRNA were undetectable in control and treated (-/-) mice ( Figure 5) . Similar results for all mRNAs examined were observed in samples analyzed from mice treated with Wy-14,643 for 11 months (data not shown). 
Discussion
In wild-type mice fed Wy-14,643, standard Coomassie staining of hepatic nuclear proteins revealed a large increase in two proteins with apparent mol. wts of~50 and~70 kDa that were both immunoreactive with a polyclonal anti-ACO antibody. While ACO is predominantly a peroxisomal or cytosolic protein, this observation is consistent with previous studies demonstrating that peroxisome proliferators can induce ACO to levels~20-fold higher than controls (6, 33) . The nuclear preps used in this work probably contained contaminating ACO because of the significant induction by Wy-14,643, as confirmed by detection with an ACO antibody. Higher levels of ACO were found in liver samples from wild-type mice fed Wy-14,643 for either 5 weeks or 11 months, before and after hepatocellular carcinomas were present, respectively (14) . Further, this induction was not observed in the PPARα-null mice treated with Wy-14,643. This observation is consistent with previous reports showing a lack of an increase in ACO mRNA and protein levels in PPARα-null mice after treatment with peroxisome proliferators (12, 13) , which is because the ACO gene has a functional PPRE in its promoter (34) .
Higher levels of hepatic CDK-1, CDK-2, CDK-4, PCNA and c-myc were found in wild-type mice fed Wy-14,643 for 5 weeks or 11 months as compared with untreated controls. For CDK-1, CDK-4 and c-myc, this effect may be caused by an increase in transcription since mRNAs for these proteins were elevated in response to Wy-14,643. Discordant expression of cell cycle regulatory proteins was also reported in rats treated with Wy-14,643 (21) (22) (23) . The present study demonstrates that the increase in CDK-1, CDK-2, CDK-4, PCNA and c-myc (i) is present after 5 weeks and persists after 11 months of treatment; (ii) is mediated by increases in mRNA (except for CDK-2 and PCNA); and (iii) is dependent on PPARα since the increases in protein and mRNA were not found in PPARα-null mice. These changes in CDK-1, CDK-2, CDK-4, PCNA and c-myc were present before and after hepatocarcinogenesis, which is consistent with reports that sustained alterations in cell proliferation contribute to the underlying mechanisms of Wy-14,643-induced hepatocarcinogenesis (16, 17, 35, 36) .
The mechanism by which PPARα regulates CDK-1, CDK-2, CDK-4, PCNA, cyclin D1 and c-myc is unclear from this study. It is important to point out that differences in expression of cyclin D protein were not observed, whereas a significant difference in cyclin D1 mRNA was noted in Wy-14,643-treated (ϩ/ϩ) mice that was not seen in (-/-) mice. This disparity may be because of the inability of the commercial antibody to differentiate among the three isoforms D1, D2 and D3 whereas the cDNA probe was specific for the D1 form of this mRNA. Further, since no differences in the mRNAs for CDK-2 and PCNA were detected, the increased levels of these proteins in response to Wy-14,643 may be the result of posttranscriptional mechanisms. Indeed, PCNA expression has been reported to be affected by post-transcriptional mechanisms (37, 38) . In contrast, the induction of CDK-1, CDK-4 and cmyc appears to be because of increased transcription that is directly or indirectly dependent on PPARα. Whether the increase in CDK-1, CDK-4, cyclin D1 or c-myc mRNA is the result of the presence of a PPRE in the promoter region of these genes or because of other upstream or downstream PPARα-dependent processes remains to be determined. Although significant differences in Wy-14,643-induced changes in proteins involved in cell proliferation and cell cycle control were found, the expression pattern was distinctly different from other reports (21) (22) (23) . Differences in the levels of cyclin B1, cyclin E or p53 as a result of treatment with Wy-14,643 were not observed. This disparity may be because of differences between mice (present study) and rats (previously reported). The mechanisms underlying this effect need to be determined.
More importantly, immunoreactive proteins with apparent mol. wts of both~50 and~70 kDa were detected in hepatic, nuclear proteins from Wy-14,643-treated wild-type mice with commercial antibodies against CDK-1, cyclin B1, c-myc and PCNA. The presence of the~70 kDa protein has been postulated to represent a complex of cyclins, CDKs and other cofactors involved in cell cycle regulation (e.g. p21) (21, 22) . This hypothesis was based on results from gel filtration experiments coupled with ELISA detection of CDKs and PCNA in collected fractions. Alternatively, we hypothesized that the immunoreactive~70 kDa protein is the result of the large induction of ACO, which could cause a concomitant increase in non-specific background of immunodetection. A large induction of ACO with apparent mol. wts of both~50 and~70 kDa using a specific polyclonal antibody was found, and this protein was a major band detected in total nuclear proteins on SDS-PAGE by Coomassie staining. Further, a relatively small quantity of pure ACO was found to be immunoreactive with commercially available antibodies against PCNA, CDK-1, cyclin B1 and c-myc. Thus these results suggest that the large increase in ACO observed on treatment with Wy-14,643 causes increased non-specific binding because of protein-antibody interactions that can interfere with differentiation of proteins with apparent mol. wt of~70 kDa.
The most difficult interpretation from these data is how these sustained alterations in cell cycle control proteins and others involved in cell proliferation contribute to the carcinogenic properties of peroxisome proliferators. Cyclin-dependent kinases, cyclins, PCNA and c-myc have critical and complex roles in cell proliferation. For example, the kinase activity of CDKs is regulated by phosphorylation, dephosphorylation or both, and by complexing with cyclins (39, 40) . Transcriptional regulation of CDK expression has also been suggested (39) (40) (41) (42) (43) . Further, substrates for phosphorylation by CDKs are variable and dependent on the phase of the cell cycle (44) (45) (46) .
In addition, fluctuations in the cellular content of CDKs and cyclins occur throughout the cell cycle, including the major transitions between G 1 , S, G 2 and M, and roles for many of these proteins are overlapping (43, 47) . Given the complexity in the roles of cell cycle control proteins and the fact that only mRNA and protein levels were measured in this study, the present data do not yield solid evidence for any specific roles for PPARα other than that it is required for the induction of these proteins. However, increased expression of CDKs, cyclins, PCNA and c-myc have all been reported in cancer cells (48) (49) (50) (51) . In fact, increased expression of PCNA and CDK-1 have been used as biomarkers of increased cell proliferation (52, 53) . Whether an increase in cyclin or CDK expression is a cause or an effect of carcinogenesis has not been elucidated. However, our results provide more evidence that this imbalance is present prior to the formation of tumors, which is suggestive of a causal relationship. Specific evidence to support the idea that increased expression of cyclins leads to tumor formation comes from mice where targeted overexpression of cyclin D1 leads to mammary tumors (54) .
Differential expression of proteins involved in cell replication has been reported in hepatocellular carcinomas (55) (56) (57) . In the current study, analysis of proteins involved in cell replication was not compared between liver tumors and the surrounding parenchyma. However, in tumor-bearing liver from rats fed Wy-14,643 for 78 weeks, expression of c-myc, c-met and PPARα mRNA is increased as a result of Wy-14,643 administration compared with control liver, yet the difference in the level of these mRNAs between tumor and the surrounding parenchyma is not substantial (58) . Thus, the mechanisms underlying the difference in cell proliferation in tumors relative to surrounding non-tumor liver (59) is unknown.
It is possible that the alterations in proteins caused by Wy-14,643 that regulate transitions in the cell cycle may cause dysregulation by improper timing of signals (i.e. G 1 signals during G 2 transition, and vice versa) thus resulting in preneoplastic cells dedifferentiating into tumor cells (22) . Alterations that result in accelerated and sustained cell proliferation may predispose cells that would normally undergo apoptosis to differentiate into tumor cells (17, 36) . For example, the sustained PPARα-dependent induction of ACO that can result in increased intracellular H 2 O 2 may cause DNA damage in cells that becomes 'fixed' as a mutation in the presence of increased cell proliferation. Interestingly, c-myc may have a critical role in both cell cycle progression and in apoptosis (60, 61) . Finally, Kupffer cell production of tumor necrosis factor (TNFα) has been implicated in the mechanism of peroxisome proliferatorinduced mitogenesis (62, 63) . Thus a role for TNFα in altering cell cycle control proteins cannot be eliminated. Clearly, elucidating the specific role or roles of these sustained imbalances in cell cycle control proteins and other proteins involved in cell proliferation will provide invaluable insight into the mechanism of peroxisome proliferator-induced hepatocarcinogenesis.
